镰状细胞病(SCD)是一种影响世界各地许多人的疾病,每年经常住院,继发于不受控制的疼痛。大麻因其在慢性疾病中治疗疼痛的药用能力而越来越多地被使用。因此,必须确定它在缓解SCD患者疼痛方面的有效性.我们系统地筛选了五个数据库的相关数据:PubMed,Medline,PubMedCentral(PMC),科克伦图书馆,谷歌学者。实施了纳入和排除标准。然后使用CochraneBias评估对随机对照试验(RCTs)进行质量评估,纽卡斯尔-渥太华观测研究工具,以及传统评论文章的叙事评论文章评估量表(SANRA)清单。从七篇文章中,收集了信息;一次系统审查,一个RCT,两项调查,一项横断面研究,一项回顾性研究,和一项基于问卷的研究。我们的评论得出结论,根据评估的文献,与阿片类药物或羟基脲的使用相比,SCD患者使用大麻要么恶化了他们的痛苦危机,要么几乎没有帮助。除了研究大麻在SCD中的长期影响的论文外,还发表了有限的RCT。我们希望在这些领域收集更多数据,以充分解决使用大麻是否对缓解SCD患者的疼痛有效。
Sickle Cell Disease (SCD) is a disease that affects many around the world and often accounts for frequent hospital admissions every year, secondary to uncontrolled pain. Marijuana is increasingly being used for its medicinal ability to treat pain in chronic medical conditions. Therefore, it is imperative to determine how effective it would be in providing pain relief to patients with SCD. We systematically screened five databases for relevant data: PubMed, Medline, PubMed Central (PMC), Cochrane Library, and Google Scholar. The inclusion and exclusion criteria were implemented. A quality appraisal was then done using the Cochrane Bias assessment for randomized controlled trials (RCTs), Newcastle-Ottawa tool for observational studies, and Scale for the Assessment of Narrative Review Articles (SANRA) checklist for traditional review articles. From seven articles, information was gathered; one systematic review, one RCT, two surveys, one cross-sectional study, one retrospective study, and one questionnaire-based study. Our review concluded that based on the literature assessed, marijuana use in SCD patients either worsened their painful crises or offered little to no help compared to opioids or hydroxyurea usage. There were limited RCTs published in addition to papers investigating the long-term effects of marijuana use in SCD. We hope that further data is gathered in these areas to sufficiently address whether cannabis use is efficacious for pain relief in patients with SCD.